Performance of integrated positron emission tomography/computed tomography for mediastinal nodal staging in non-small cell lung carcinoma.

Integrated positron emission tomography (PET)/CT is routinely used for mediastinal nodal staging of non-small cell lung carcinoma in centers throughout the world. This modality is the most accurate noninvasive means by which to identify metastatic disease in mediastinal lymph nodes. This article reviews the evidence supporting the use of PET/CT and discusses the clinical applicability of this modality.

[1]  Paul Kinahan,et al.  A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  R. Cerfolio,et al.  Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. , 2003, The Journal of thoracic and cardiovascular surgery.

[3]  C. Dooms,et al.  Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Michael K Gould,et al.  Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). , 2007, Chest.

[5]  R. Cerfolio,et al.  Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. , 2006, The Journal of thoracic and cardiovascular surgery.

[6]  F. Detterbeck,et al.  A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  V. Rusch,et al.  Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. , 2003, The Journal of thoracic and cardiovascular surgery.

[8]  K. Welch,et al.  Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis. , 2012, Clinical lung cancer.

[9]  K. Nackaerts,et al.  Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lu , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Richards,et al.  Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. , 2000, The Annals of thoracic surgery.

[11]  A. Bezjak,et al.  Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. , 2007, The Journal of thoracic and cardiovascular surgery.

[12]  N. Altorki,et al.  Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. , 2004, The Annals of thoracic surgery.

[13]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[14]  Y. Ung,et al.  Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Y. Ung,et al.  Positron Emission Tomography in Staging Early Lung Cancer , 2009, Annals of Internal Medicine.

[16]  Harry J M Groen,et al.  Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restaging after treatment for locally advanced non-small cell lung cancer. , 2009, Lung cancer.

[17]  M. King,et al.  Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Alfred A Bartolucci,et al.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. , 2004, The Annals of thoracic surgery.

[19]  A. Fischman,et al.  FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. , 2002, Lung cancer.

[20]  H. Schäfers,et al.  Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. , 2004, The Journal of thoracic and cardiovascular surgery.

[21]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[22]  D. Ettinger,et al.  Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01 , 2002 .

[23]  M. Serra-Mitjans,et al.  Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  A. Dirksen,et al.  Preoperative staging of lung cancer with combined PET-CT. , 2009, The New England journal of medicine.